These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 11866670)

  • 21. Pathways and Drugs in Pulmonary Arterial Hypertension - Focus on the Role of Endothelin Receptor Antagonists.
    Madonna R; Cocco N; De Caterina R
    Cardiovasc Drugs Ther; 2015; 29(5):469-79. PubMed ID: 26145170
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endothelin receptor antagonists and their developing role in cardiovascular therapeutics.
    Dupuis J
    Can J Cardiol; 2000 Jul; 16(7):903-10. PubMed ID: 10934309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. No redistribution of lung blood flow by inhaled nitric oxide in endotoxemic piglets pretreated with an endothelin receptor antagonist.
    Trachsel S; Hambraeus-Jonzon K; Bergquist M; Martijn C; Chen L; Hedenstierna G
    J Appl Physiol (1985); 2015 Mar; 118(6):768-75. PubMed ID: 25549764
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The therapeutic potential of endothelin-1 receptor antagonists and endothelin-converting enzyme inhibitors on the cardiovascular system.
    Doggrell SA
    Expert Opin Investig Drugs; 2002 Nov; 11(11):1537-52. PubMed ID: 12437501
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endothelin-1 and endothelin receptor antagonists as potential cardiovascular therapeutic agents.
    Ergul A
    Pharmacotherapy; 2002 Jan; 22(1):54-65. PubMed ID: 11794430
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endothelin-1 and endothelin receptor antagonists in cardiovascular remodeling.
    Kirchengast M; Münter K
    Proc Soc Exp Biol Med; 1999 Sep; 221(4):312-25. PubMed ID: 10460693
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endothelin: 30 Years From Discovery to Therapy.
    Barton M; Yanagisawa M
    Hypertension; 2019 Dec; 74(6):1232-1265. PubMed ID: 31679425
    [TBL] [Abstract][Full Text] [Related]  

  • 28. YM598, an orally active ET(A) receptor antagonist, ameliorates the progression of cardiopulmonary changes and both-side heart failure in rats with cor pulmonale and myocardial infarction.
    Fujimori A; Miyauchi T; Sakai S; Yuyama H; Iemitsu M; Sanagi M; Sudoh K; Goto K; Shikama H; Yamaguchi I
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S354-7. PubMed ID: 15838319
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Idiopathic pre-capillary pulmonary hypertension in patients with end-stage kidney disease: effect of endothelin receptor antagonists.
    Nishimura M; Tokoro T; Yamazaki S; Hashimoto T; Kobayashi H; Ono T
    Clin Exp Nephrol; 2017 Dec; 21(6):1088-1096. PubMed ID: 27757709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The rise and fall of endothelin receptor antagonists in congestive heart failure.
    Handoko ML; de Man FS; Vonk-Noordegraaf A
    Eur Respir J; 2011 Mar; 37(3):484-5. PubMed ID: 21357921
    [No Abstract]   [Full Text] [Related]  

  • 31. Potential Role of Endothelin in Early Vascular Aging.
    Trindade M; Oigman W; Fritsch Neves M
    Curr Hypertens Rev; 2017; 13(1):33-40. PubMed ID: 28413991
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Endothelin-1 and cardiovascular diseases].
    Cracowski JL; Stanke F; Bessard G
    Rev Med Interne; 1999 Jul; 20(7):589-96. PubMed ID: 10434349
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The endothelin system in pulmonary hypertension.
    Michel RP; Langleben D; Dupuis J
    Can J Physiol Pharmacol; 2003 Jun; 81(6):542-54. PubMed ID: 12839266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension.
    Kim NH; Rubin LJ
    J Cardiovasc Pharmacol Ther; 2002 Jan; 7(1):9-19. PubMed ID: 12000973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bosentan: a dual endothelin receptor antagonist.
    Rubin LJ; Roux S
    Expert Opin Investig Drugs; 2002 Jul; 11(7):991-1002. PubMed ID: 12084009
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chronic therapy with an ET(A/B) receptor antagonist in conscious dogs during progression of congestive heart failure. Intracellular Ca(2+) regulation and nitric oxide mediated coronary relaxation.
    Shen YT; Buie PS; Lynch JJ; Krause SM; Ma XL
    Cardiovasc Res; 2000 Nov; 48(2):332-45. PubMed ID: 11054479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A review of sitaxsentan sodium in patients with pulmonary arterial hypertension.
    Waxman AB
    Vasc Health Risk Manag; 2007; 3(1):151-7. PubMed ID: 17583185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renal and systemic effects of chronic blockade of ET(A) or ET(B) receptors in normal rats and animals with experimental heart failure.
    Francis B; Winaver J; Karram T; Hoffman A; Abassi Z
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S54-8. PubMed ID: 15838359
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological potential of endothelin receptors agonists and antagonists.
    Patocka J; Merka V; Hrdina V; Hrdina R
    Acta Medica (Hradec Kralove); 2005; 48(2):67-73. PubMed ID: 16259315
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pulmonary arterial hypertension. Therapy with the endothelin-1 receptor antagonist bosentan].
    Musch A
    Med Monatsschr Pharm; 2006 Jul; 29(7):242-5. PubMed ID: 16866076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.